Neoleukin Therapeutics (NASDAQ:NLTX) Shares Gap Down to $17.01

Neoleukin Therapeutics (NASDAQ:NLTX)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $19.33, but opened at $17.01. Neoleukin Therapeutics shares last traded at $17.01, with a volume of 330,000 shares traded.

Several research analysts have recently weighed in on NLTX shares. Bank of America started coverage on Neoleukin Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research raised Neoleukin Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Saturday. Canaccord Genuity reissued a “buy” rating and issued a $20.00 price objective on shares of Neoleukin Therapeutics in a research report on Thursday, June 25th. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Neoleukin Therapeutics in a research note on Monday, May 18th. Finally, BidaskClub upgraded Neoleukin Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 19th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $21.14.

The company has a debt-to-equity ratio of 0.08, a quick ratio of 24.92 and a current ratio of 24.92. The business has a 50 day simple moving average of $13.82 and a 200-day simple moving average of $11.61.

Neoleukin Therapeutics (NASDAQ:NLTX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Equities research analysts expect that Neoleukin Therapeutics will post -0.96 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in NLTX. UBS Group AG boosted its stake in Neoleukin Therapeutics by 62.2% during the 1st quarter. UBS Group AG now owns 6,486 shares of the company’s stock valued at $74,000 after purchasing an additional 2,486 shares during the last quarter. Citigroup Inc. boosted its stake in shares of Neoleukin Therapeutics by 27.0% in the 4th quarter. Citigroup Inc. now owns 6,349 shares of the company’s stock worth $78,000 after buying an additional 1,349 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Neoleukin Therapeutics in the 4th quarter worth approximately $125,000. Janus Henderson Group PLC purchased a new position in shares of Neoleukin Therapeutics in the 4th quarter worth approximately $146,000. Finally, State Street Corp boosted its stake in shares of Neoleukin Therapeutics by 13.2% in the 1st quarter. State Street Corp now owns 13,753 shares of the company’s stock worth $157,000 after buying an additional 1,600 shares during the last quarter. Institutional investors and hedge funds own 59.29% of the company’s stock.

Neoleukin Therapeutics Company Profile (NASDAQ:NLTX)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.

Featured Story: Trading Strategy Methods for Individual Investors

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.